Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00382408 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001
A Phase 3 study of Respiratory Tract Diseases, sponsored by Duramed Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,040
- Enrollment target
- 2
- Study locations
NCT00382408 is a Phase 3 study of Respiratory Tract Diseases that has completed, run by Duramed Research. The registered enrollment target is 4,040 participants, above the 1,768-participant average among 8 other Respiratory Tract Diseases trials with a reported enrollment target (129% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT00382408, a Phase 3 study of Respiratory Tract Diseases, has completed, sponsored by Duramed Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,040 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of oral DR-5001 in reducing the attack rate of febrile acute respiratory disease caused by type-4 and type-7 adenovirus as well as determine its immunogenicity.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL DR-5001
Study Locations (2)
Illinois
- Duramed Investigational Site - Great Lakes
South Carolina
- Duramed Investigational Site - Fort Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,040 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00382408
The ClinicalTrials.gov registry entry for NCT00382408 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,040 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,768-participant average among 8 other Respiratory Tract Diseases trials with a reported enrollment target (129% higher). The listed sponsor is Duramed Research, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Respiratory Tract Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00382408 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, South Carolina.
Frequently Asked Questions
What is clinical trial NCT00382408 about?
NCT00382408 is a clinical study titled "A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001". This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of oral DR-5001 in reducing the attack rate of febrile acute respiratory disease caused by type-4 and type-7 adenovirus as well as determine its immunogenicity.
What is the current status of trial NCT00382408?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,040 participants. The study started on 2006-09. Estimated completion is 2007-12.
What conditions does trial NCT00382408 study?
This clinical trial studies the following conditions: Respiratory Tract Diseases.
What interventions are being tested in trial NCT00382408?
The interventions under investigation include: Placebo (OTHER), DR-5001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00382408?
This trial is sponsored by Duramed Research, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00382408 being conducted?
This trial has 2 study locations across Illinois, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Tract Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults
COMPLETED · Phase 3
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
Collection of Lung Fluid and Tissue Samples for Research
RECRUITING
-
AeviceMD for Detection of Wheeze in Pediatric and Adult Populations
RECRUITING
-
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
ACTIVE NOT RECRUITING · Phase 2
-
Aventus Thrombectomy System Pulmonary Embolism Clinical Study
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.